Candel Therapeutics grants Ostrovsky 315,000 options

The options have a stated expiration date of November 3, 2036.

Available on EDGAR 11/05/2026 - 04:31 PM EST Accepted by SEC EDGAR 11/05/2026 - 04:24 PM EST

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Candel Therapeutics, Inc. (CADL) General Counsel Maria Ostrovsky was granted 315,000 stock options on November 3, 2026, at an exercise price of $8.82 per share. Her reported post-transaction option position was 315,000. Twenty-five percent vest and become exercisable on November 3, 2027; the remainder vests in 36 equal monthly installments, subject to her continued service on each vesting date.

Insider Trade Summary

Grant/Award: 315,000 shares

Grant/Award 1 txn

Insider Ostrovsky Maria

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F1	315,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 315,000 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 315,000 contracts (Direct)

Footnotes (1)

F1. 25% of the shares underlying this option shall vest and become exercisable on November 3, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Stock option grant: 315,000 stock options Exercise price: $8.82 per share Initial vesting: 25% +2 more

5 metrics

Stock option grant 315,000 stock options Granted November 3, 2026

Exercise price $8.82 per share For the stock options granted November 3, 2026

Initial vesting 25% Vests and becomes exercisable November 3, 2027, subject to continued service

Remaining vesting installments 36 equal monthly installments Subject to continued service on each vesting date

Option expiration date November 3, 2036 Stock options granted November 3, 2026

Key Terms

Stock Option (Right to Buy), vest and become exercisable, equal monthly installments

3 terms

Stock Option (Right to Buy) financial

"315,000 Stock Option (Right to Buy)"

vest and become exercisable financial

"shall vest and become exercisable on November 3, 2027"

equal monthly installments financial

"thirty-six (36) equal monthly installments thereafter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CADL stock options did Maria Ostrovsky receive?

Maria Ostrovsky, Candel Therapeutics’ General Counsel, was granted 315,000 stock options on November 3, 2026. The options cover common stock and have an exercise price of $8.82 per share.

When do Maria Ostrovsky’s CADL stock options expire?

The options have a stated expiration date of November 3, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ostrovsky Maria

(Last)

(First)

(Middle)

C/O CANDEL THERAPEUTICS, INC

117 KENDRICK STREET, SUITE 450

(Street)

NEEDHAM

MASSACHUSETTS

02494

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Candel Therapeutics, Inc. [ CADL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$8.82	11/03/2026		A		315,000		⁽¹⁾	11/03/2036	Common Stock	315,000	$0	315,000	D

Explanation of Responses:

1. 25% of the shares underlying this option shall vest and become exercisable on November 3, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Charles Schoch, as Attorney-In-Fact for Maria Ostrovsky	11/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR